{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06528314",
            "orgStudyIdInfo": {
                "id": "AK-US-001-0106"
            },
            "organization": {
                "fullName": "Akero Therapeutics, Inc",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH",
            "officialTitle": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrohosis Due to NASH/MASH",
            "therapeuticArea": [
                "Gastroenterology"
            ],
            "study": "a-study-evaluating-efruxifermin-in-subjects-with-compensated-cirrhosis-due-to-nash-mash"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-10",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2029-09",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-10",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-06-28",
            "studyFirstSubmitQcDate": "2024-07-25",
            "studyFirstPostDateStruct": {
                "date": "2024-07-30",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2024-07-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-30",
                "type": "ESTIMATED"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Akero Therapeutics, Inc",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH."
        },
        "conditionsModule": {
            "conditions": [
                "NASH - Nonalcoholic Steatohepatitis",
                "MASH - Metabolic Dysfunction-Associated Steatohepatitis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 1150,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "EFX 50 mg",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Efruxifermin"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Efruxifermin",
                    "description": "Administered by subcutaneous injection",
                    "armGroupLabels": [
                        "EFX 50 mg"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Administered by subcutaneous injection",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Time from randomization to first occurrence of disease progression as measured by composite of protocol-specified clinical events",
                    "timeFrame": "5 years"
                },
                {
                    "measure": "Cohort 1 only: \u2265 1 stage improvement in fibrosis and no worsening of steatohepatitis",
                    "description": "Based on NASH CRN fibrosis score (scored by a fibrosis score of 0-4, where 0 = no fibrosis, 1 = centrilobular pericellular fibrosis, 2 = centrilobular and periportal fibrosis, 3 = bridging fibrosis, 4 = cirrhosis)",
                    "timeFrame": "96 Weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change from baseline of non-invasive markers of liver fibrosis",
                    "description": "ELF (scale of 6.7 to 11.3 with higher scores indicative of increased fibrosis)",
                    "timeFrame": "96 Weeks"
                },
                {
                    "measure": "Change from baseline of non-invasive markers of liver fibrosis",
                    "description": "Pro-C3 (ug/L)",
                    "timeFrame": "96 Weeks"
                },
                {
                    "measure": "Change from baseline of non-invasive markers of liver fibrosis",
                    "description": "Liver stiffness assessed by transient elastography (FibroScan\u00ae) (kPa)",
                    "timeFrame": "96 Weeks"
                },
                {
                    "measure": "Change from baseline of non-invasive markers of liver fibrosis",
                    "description": "FAST score (varied on a scale from 0 to 1, with the patients being classified as having low \\[\\<0.35\\], intermediate \\[0.35-0.67\\], or higher \\[\\>0.67\\] probability of having significant inflammatory activity and fibrosis)",
                    "timeFrame": "96 Weeks"
                },
                {
                    "measure": "Change from baseline of markers of liver injury",
                    "description": "ALT (U/L) and AST (U/L)",
                    "timeFrame": "96 Weeks"
                },
                {
                    "measure": "Change from baseline of lipoproteins",
                    "description": "Total cholesterol (mg/dL), Triglycerides (mg/dL), HDL-C (mg/dL), Non-HDL-C (mg/dL), and LDL-C (mg/dL)",
                    "timeFrame": "96 Weeks"
                },
                {
                    "measure": "Change from baseline of markers of insulin sensitivity and glycemic control",
                    "description": "HbA1c (%)",
                    "timeFrame": "96 Weeks"
                },
                {
                    "measure": "Change from baseline of markers of insulin sensitivity and glycemic control",
                    "description": "C-Peptide (ng/mL)",
                    "timeFrame": "96 Weeks"
                },
                {
                    "measure": "Change from baseline of markers of insulin sensitivity and glycemic control",
                    "description": "Adiponectin (mg/L)",
                    "timeFrame": "96 Weeks"
                },
                {
                    "measure": "Change from baseline of markers of insulin sensitivity and glycemic control",
                    "description": "Insulin (mIU/L)",
                    "timeFrame": "96 Weeks"
                },
                {
                    "measure": "Change from baseline of markers of insulin sensitivity and glycemic control",
                    "description": "HOMA-IR (\u2265 2.5 indicates insulin resistance)",
                    "timeFrame": "96 Weeks"
                },
                {
                    "measure": "Change from baseline of body weight (kg)",
                    "timeFrame": "96 Weeks"
                },
                {
                    "measure": "To assess the safety and tolerability of EFX through the reporting of extent of exposure (weeks)",
                    "timeFrame": "96 Weeks"
                },
                {
                    "measure": "To assess the safety and tolerability of EFX through the reporting of adverse events (frequency of events)",
                    "timeFrame": "96 Weeks"
                },
                {
                    "measure": "To assess the safety and tolerability of EFX through the reporting of adverse events (severity of events)",
                    "timeFrame": "96 Weeks"
                },
                {
                    "measure": "Number of participants with abnormal laboratory tests results, abnormal ECGs, abnormal ultrasounds, abnormal vital sign assessments",
                    "timeFrame": "96 Weeks"
                },
                {
                    "measure": "Cohort 1 only: \u2265 1 stage improvement in fibrosis and no worsening of steatohepatitis",
                    "description": "Based on NASH CRN fibrosis score (scored by a fibrosis score of 0-4, where 0 = no fibrosis, 1 = centrilobular pericellular fibrosis, 2 = centrilobular and periportal fibrosis, 3 = bridging fibrosis, 4 = cirrhosis)",
                    "timeFrame": "5 Years"
                },
                {
                    "measure": "Cohort 1 only: \u2265 1 stage improvement in fibrosis",
                    "description": "Based on NASH CRN fibrosis score (scored by a fibrosis score of 0-4, where 0 = no fibrosis, 1 = centrilobular pericellular fibrosis, 2 = centrilobular and periportal fibrosis, 3 = bridging fibrosis, 4 = cirrhosis)",
                    "timeFrame": "96 Weeks, 5 Years"
                },
                {
                    "measure": "Cohort 1 only: Resolution of NASH/MASH",
                    "description": "Based on NAS (scored by 0-1 for steatosis, 0-3 for inflammation, and 0-2 for ballooning)",
                    "timeFrame": "96 Weeks, 5 Years"
                },
                {
                    "measure": "Cohort 1 only: Resolution of NASH/MASH and a \u2265 1 stage improvement in fibrosis",
                    "description": "Based on NAS (scored by 0-1 for steatosis, 0-3 for inflammation, and 0-2 for ballooning) and NASH CRN fibrosis score (scored by a fibrosis score of 0-4, where 0 = no fibrosis, 1 = centrilobular pericellular fibrosis, 2 = centrilobular and periportal fibrosis, 3 = bridging fibrosis, 4 = cirrhosis)",
                    "timeFrame": "96 Weeks, 5 Years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Cohort 1: Biopsy proven compensated cirrhosis (fibrosis stage 4) due to NASH/MASH\n* Cohort 2: Biopsy proven or non-invasively diagnosed compensated cirrhosis (fibrosis stage 4) due to NASH/MASH\n\nExclusion Criteria:\n\n* Other causes of liver disease based on medical history and/or liver histology and/or central laboratory results\n* Type 1 diabetes or unstable Type 2 diabetes\n* Any current or prior history of decompensated liver disease\n\nOther inclusion and exclusion criteria may apply",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "80 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Akero Study Director",
                    "role": "CONTACT",
                    "phone": "650-487-6488",
                    "email": "AkeroSynchrony@akerotx.com"
                }
            ],
            "locations": [
                {
                    "facility": "Akero Clinical Study Site",
                    "status": "RECRUITING",
                    "city": "Marietta",
                    "state": "Georgia",
                    "zip": "30060",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Akero Site 9111",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.9526,
                        "lon": -84.54993
                    }
                },
                {
                    "facility": "Akero Clinical Study Site",
                    "status": "RECRUITING",
                    "city": "Houma",
                    "state": "Louisiana",
                    "zip": "70363",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Akero Site 0112",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.59577,
                        "lon": -90.71953
                    }
                },
                {
                    "facility": "Akero Clinical Study Site",
                    "status": "RECRUITING",
                    "city": "Metairie",
                    "state": "Louisiana",
                    "zip": "70006",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Akero Site 0109",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.98409,
                        "lon": -90.15285
                    }
                },
                {
                    "facility": "Akero Clinical Study Site",
                    "status": "RECRUITING",
                    "city": "Springboro",
                    "state": "Ohio",
                    "zip": "45066",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Akero Site 9233",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.55228,
                        "lon": -84.23327
                    }
                },
                {
                    "facility": "Akero Clinical Study Site",
                    "status": "RECRUITING",
                    "city": "Columbia",
                    "state": "South Carolina",
                    "zip": "29204",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Akero Site 0151",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.00071,
                        "lon": -81.03481
                    }
                },
                {
                    "facility": "Akero Clinical Study Site",
                    "status": "RECRUITING",
                    "city": "Hermitage",
                    "state": "Tennessee",
                    "zip": "37076",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Akero Site 9123",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.19617,
                        "lon": -86.6225
                    }
                },
                {
                    "facility": "Akero Clinical Study Site",
                    "status": "RECRUITING",
                    "city": "Wichita Falls",
                    "state": "Texas",
                    "zip": "76301",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Akero Site 9247",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.91371,
                        "lon": -98.49339
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000005234",
                    "term": "Fatty Liver"
                },
                {
                    "id": "D000065626",
                    "term": "Non-alcoholic Fatty Liver Disease"
                }
            ],
            "ancestors": [
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M8375",
                    "name": "Fatty Liver",
                    "asFound": "Steatohepatitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11103",
                    "name": "Liver Cirrhosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M30540",
                    "name": "Non-alcoholic Fatty Liver Disease",
                    "asFound": "Nonalcoholic Steatohepatitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T5868",
                    "name": "Visceral Steatosis",
                    "asFound": "Steatohepatitis",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}